

CHRONIC BETA-ADRENERGIC BLOCKADE ENHANCES GROWTH VELOCITY TO GROWTH HORMONE RELEASING HORMONE IN GROWTH HORMONE DEFICIENT CHILDREN (GHD). V. Mericq, F. Cassorla, H. Garcia, A. Avila, A. Boric and G. Merriam. IDIMI. University of Chile DBB, NICHD, Bethesda, Maryland, U.S.A.

GHRH is effective in improving the growth velocity in GHD children. Atenolol is a beta adrenergic antagonist which acutely inhibits somatostatin secretion. To determine whether the combined therapy of GHRH+Atenolol improves the growth response to GHRH in GHD children we studied in a double blind, randomized trial 11 prepupertal GHD children (5F,6M) divided in 2 groups: Group A n=5 (3F,2M), chronological age (CA) 8 ± 2.7 years, bone age (BA) 4.9 ± 2.8 years received daily GHRH 20 ug/kg sc + daily oral Atenolol (1mg/kg). Group B n=6 (2F, 4M) CA 10.6 ± 3.7 years, BA 5.5 ± 2.9 years received daily GHRH 20 ug/kg sc + placebo. The children were admitted to the hospital before and after 1 year of treatment to measure GH every 20 minutes for 24 hours and height was determined every 6 months. Growth velocity increased in group A from 3.3 ± 0.6 cm/year to 6.7 ± 1.2 cm/year ($p < 0.0005$) and in group B from 3.2 ± 0.8 cm/year to 5.4 ± 1.4 cm/year ($p < 0.025$). Growth velocity was significantly different in group A compared to group B ($p < 0.05$). Mean 24 hour GH secretion increased in group A from 1.8 ± 1.1 to 2.2 ± 1.2 ng/ml (NS) and in group B from 1.2 ± 0.14 to 1.6 ± 0.4 ng/ml (NS). This study demonstrate that the beta-adrenergic blockade with Atenolol enhances the growth velocity to GHRH in GHD children. This suggests that the growth velocity in GHD children treated with GHRH can be potentiated with an agent that blocks Somatostatin secretion.

THE CIRCULATING LEVELS IGF-2 ARE INCREASED IN SMALL FOR GESTATIONAL AGE (SGA) INFANTS WHO SHOW EVIDENCE OF CATCH-UP-GROWTH (CUG) DURING THE FIRST YEAR OF LIFE. H. Garcia, C. Henriquez, F. Ugarte, G. Iñiguez, F. Beas, E. Fernandez, A. Avila. IDIM, Fac. de Med., Universidad de Chile.

To study the influence of IGF-1 and IGF-2 levels in the catch-up-growth (CUG) of small for gestational age (SGA) infants, we followed 32 newborns (18 boys and 14 girls) with birth weight of 2344 ± 195 g and birth length of 45.7 ± 2 cm, during the first year of life. We measured weight, length, IGF-1 and IGF-2 at 0, 3, 6, 9 and 12 months of age. CUG was defined as an increase in length 2 score greater than 1 SD at 6 months of age, based upon the fact that accelerated growth, when observed in CUG (+) infants, occurs during this period. We compared the concentrations of IGF-1 and 2 between the infants who demonstrated evidence of CUG and those who did not.

Results: IGF-2 (pg/ml)

N/O	0	3	6	9
CUG+16/10/6	31.0±25.2	189.5±110.1	123.7±32.5	130.7±34.9
cug-16 8/8	16.1±14.4	120.9±28.9	93.9±24.3	126.3±28.6
	P=NS	P<0.05	P<0.02	P=NS

Height Z score was lower in CUG(+)-infants at birth and increased during the first 6 months of life. IGF-2 levels were significantly greater at 3 and 6 months in CUG (+) infants. There were no differences in IGF-2 levels at 0, 9, 12 months, nor in IGF-1 levels at any time. We conclude that circulating IGF-2 levels at 3 and 6 months correlate with height velocity. This growth factor may be involved in the mechanism of CUG in SGA age infants. This suggests that IGF-2 may be useful as a potential therapeutic agent for the treatment of SGA infants who do not demonstrate evidence of CUG. Financial support: Grant 91-1274, Fondecyt.

TREATMENT OF CHRONIC RENAL FAILURE WITH GROWTH-HORMONE-RELEASING HORMONE. T. Pasqualini, S. Moyano, P. Fainsteins-Day, R. Gutman, A. Eymann, J. Ferraris. Hospital Italiano, Departamento de Pediatría, Buenos Aires, Argentina.

Growth retardation is common in children with chronic renal failure (CRF) and after renal transplantation (Tx). For this reason we treated 9 children (3 on conservative treatment, CT; 3 on dialysis, D; and 3 Tx), aged 1.6 to 14.0 (x±sd; 8.1 ± 4.3) years, with twice daily subcutaneous injections of growth hormone-releasing analogue, GHRH (1-29)NH₂ Serono at a mean dose of 26 ± 7 ug/kg/day, during 2 to 6 months. Mean serum urea and creatinine remained stable, although in CT patients serum creatinine increased moderately. Before treatment, mean bone age was 5.2 ± 3.1 years, height SDS -2.2 ± 0.6 and growth velocity 4.5 ± 2.9 cm/year (-2.3 ± 2.0 DS for chronological age). Mean nocturnal spontaneous growth hormone (xGH) was 3.3 ± 1.6 ng/ml, smooth line 1.6 ± 0.9 ng/ml, amplitude 5.4 ± 2.6 ng/ml, number of peaks 3.8 ± 1.3 and growth hormone (GH) response to GHRH test (1 ug/kg IV) 61.7 ± 52.5 ng/ml. Five patients, all 3 on CT included, increased the height velocity from 3.8 ± 1.6 to 8.0 ± 2.6 cm/year. The peak GH response to GHRH was significantly higher in the group of growth non-responders than the responders ($p < 0.05$). Conclusion: GHRH treatment increased growth velocity in 55% of our patients. All CT patients had a worthwhile response to therapy: height velocity increased by more than 2 cm/year. Growth response to GHRH was lower when GH response to GHRH test was high, suggesting peripheral resistance to the biological action of GH.

EVALUATION OF EFFICACY AND SAFETY OF RECOMBINANT HUMAN GROWTH HORMONE (rhGH) IN PRE-PUBERTAL SHORT CHILDREN WITH CHRONIC RENAL FAILURE (CRF). MCS. Boguszewski, R. Sandrini, I. Cat and L. de Lacerda. Division of Endocrine Dept of Pediatrics, UFPR, Curitiba, Paraná, Brazil.

Growth retardation is a common problem in children with CRF more pronounced the earlier the renal failure occurs. This study was designed to evaluate the efficacy and safety of rhGH treatment in pre-pubertal children with CRF and short stature. 10 patients (5 girls aged 5.9-11.5, mean 8.1 and 5 boys aged 3.8-12.2, mean 8.0) were enrolled in the study according to the following criteria: CRF diagnosed at least 12 months prior to entry into the study; glomerular filtration rate (GRF) 50 ml/min/1.73m² body surface area (Schwartz's formula) and normal thyroid function. rhGH (Genotropin R), 1 IU/kg/week was given in daily sc injections for 12 months. Clinical and biochemical assessment was carried out every 3 months. Mean height velocity (HV) increased from 4.5 to 8.6 cm/year ($p < 0.01$); mean HV -SDS increased from -1.58 to 2.92 ($p < 0.01$); mean height SDS improved from -3.3 to -2.8 ($p < 0.01$). Mean weight gain was 3.2 kg and mean bone age advanced 1 year. Two girls started puberty after 6 months of therapy. GRF increased significantly ($p < 0.05$) at 6 months and returned to pre-treatment values at 1 year of therapy. Serum phosphate and insulin increased ($p < 0.01$) at 12 months. Other biochemical parameters (calcium, alkaline phosphatase, creatinine, T₃, T₄, TSH, hematocrit, cholesterol, tryglycerides, Na, K, BUN, glucose and fructosamine) did not change. No side effects were observed. These results confirm previous reports on the effectiveness of rhGH in increasing height velocity of short slowly growing patients with CRF.

ANDROGEN PATTERN IN PREPUBERTAL HYPERTRICHOSIS. H. Gryngarten, ME. Escobar, S. Campo, S. Ayuso, P. Bedecarrás, C. Bergadá. CEDIE. División de Endocrinología. Hospital de Niños R. Gutierrez. Buenos Aires, Argentina.

The cause of prepupertal hypertrichosis (H) is unknown. Plasmatic androgen levels were determined in 17 girls with H, (ca: X±SD: 5.9 ± 1.41 years), 11 girls with precocious pubarche (PP) and 9 normal prepupertal girls (CP).

All of them were assessed according to their distribution score of vellus hair. Group H. was characterized by excessive growth of vellus hair (score > 7), CP showed normal distribution and PP group had pubic hair II-III without excessive growth of vellus hair (score < 5). 17OH Progesterone, Androstenedione (A), DHEA-S, Testosterone (T), SHBG and 3 Androstanediol glucuronide (3 AG) were measured by RIA.

	# DHEA-S ng/ml	# A ng/dl	# AG ng/dl
CP	210.66 ± 42.58	46.33 ± 8.91	62.11 ± 8.32
H	203.05 ± 44.77	54.76 ± 6.14	111.41 ± 13.73
PP	782.54 ± 151.84*	81.81 ± 15.93	130.72 ± 33.19
# X±SE	* p < 0.02		

Normal levels of A and DHEA-S and elevated 3 AG levels suggest an increase in the peripheral activity of 5 reductase in most prepupertal girls with hypertrichosis.

MOLECULAR ANALYSES OF STEROID 6α-REDUCTASE 2 GENE IN MALE PSEUDOHERMAPHRODITES. Mendonça BB; Arnold IJP; Bloise W; Nicolau W; Wajchenberg BL; Wilson JD; Russell DW. Dept. of Molecular Genetics and Internal Medicine, UT Southwestern Medical Center, Dallas, USA., Gonads and Intersex Unit, Division of Endocrinology, University of São Paulo, Brasil.

We analyzed the molecular genetics and biochemistry of 5α-reductase 2 (5α-RD 2) deficiency in 7 patients with male pseudohermaphroditism. The diagnosis of 5α-RD 2 was established by clinical data (all patients were born with ambiguous genitalia-microphallus, perineal hypospadias and bifid scrotum) and were raised as females until 6-15 y when they change to male gender) and by T/DHT ratio over normal in basal condition in postpubertal cases or after hCG in prepupertal cases. (Normal basal T/DHT ratio = 14 ± 5.2 ; after hCG = 13.8 ± 5.5). The 5 exons of the 5α-RD 2 gene were amplified by polymerase chain reaction (PCR) using exons-specific pairs of oligonucleotides, with a thermocycler program of 35 cycles of 1 min/94°C, 3 min/68°C. The mutations and the presence of homozygosity or compound heterozygosity were detected by SSCP analyses and the DNA sequences of the putative mutations were determined by PCR sequencing.

CASE	CA (ys)	T/DHT	Molecular Defects		
			Type	Exon	Mutation
1#	6	44	nonsense	4	C→T, R227*
2#	9	36			
3	14	30	missense	3	G→A, G183S
4√	13	37		2	A→G, Q126R
5√	14	40	missense	4	A→G, N193S
6√	19	46			
7	15	83	missense	5	C→T, R246W

#: Siblings √: Siblings

We found four different mutations in our patients. These results confirm the genetic heterogeneity of the 5α-RD 2. We conclude that in all patients studied mutations in type 2 gene account for 5α-reductase 2 deficiency.